Recent events
Recent events tied to this brand in public sources.
Back to profile8 entries
2022
Servier reports 2020/21 annual results
Servier published results for its 2020/21 financial year, reporting consolidated revenue of €4.725 billion, up 4.3% at constant exchange rates.
2021
Servier Ukraine receives Best Place to Work certification
Servier Ukraine was recognized as one of the best places to work in Ukraine for 2021 after an employee survey and HR assessment.
2021
Servier fined over Mediator
A French court fined drug maker Servier €2.7 million after finding it guilty of aggravated deceit and involuntary manslaughter over the weight-loss drug Mediator. The court said Servier knew of the risks for years and failed to take necessary measures.
2021
Paris court finds Servier guilty over Mediator and imposes fine
A Paris court found Servier guilty of manslaughter and deception over the weight-loss drug Mediator and fined the company 2.7 million euros.
2021
Elsevier releases updated DDIRC 2.0 in PharmaPendium
Elsevier, together with pharmaceutical collaborators, further refined and extended its drug-drug interaction risk calculator in PharmaPendium. The DDIRC 2.0 release includes updated visualizations and filters, a more comprehensive dataset, and improved dossier submission support.
2020
Servier completes acquisition of Symphogen
Servier announced that it had completed its acquisition of Symphogen A/S. Symphogen will operate as an antibody center of excellence within Servier and retain operational autonomy, its employees and its headquarters in Ballerup, Denmark.
2019
Servier acquires worldwide rights to Pixuvri
Servier acquired CTI BioPharma’s Pixuvri therapy after the companies completed an Asset Purchase Agreement transferring worldwide rights to Servier.
2019
Servier completes acquisition of PIXUVRI rights
Servier announced that it acquired PIXUVRI from CTI BioPharma and that an asset purchase agreement transferred worldwide rights to Servier.